Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16289468 | 1.00 | POLB (0.79) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL17231094 | 0.93 | POLB (0.69) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL5180666 | 0.92 | POLB (0.67) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL10947631 | 0.91 | POLB (0.66) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL23211670 | 0.91 | POLB (0.86) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL23211669 | 0.91 | POLB (0.86) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL16257644 | 0.89 | POLB (0.64) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL13213637 | 0.89 | POLB (0.64) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL15146153 | 0.89 | POLB (1.00) | POLBABL1RIN1RNASE1P2RY6 | |
| SCHEMBL6206103 | 0.86 | POLB (0.78) | POLBABL1RIN1RNASE1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-10-27 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-7019127-B2 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED (GB) | 2006-03-28 | — | — | US | disclosed |
| US-20050240015-A1 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| EP-1325927-A2 | Synthesis of oligonucleotides | Avecia Limited (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED | 2003-05-01 | — | — | US | disclosed |
| EP-1003758-B1 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA LTD (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6506894-B1 | Phosphonation; oxidation in situ with sulfur transfer agent | AVECIA LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
| US-20160311858-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | NUDT1, POLR2E, POLRMT | POLB 17/4885ABL1 2045/4885RIN1 4428/4885 |
| US-20050240015-A1 | Solution phase synthesis of oligonucleotides | NUDT1, POLR2E, POLRMT | POLB 17/4885ABL1 2045/4885RIN1 4428/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | POLB 4572/4885ABL1 3088/4885RIN1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.